NYSE:TARO - Taro Pharmaceutical Industries Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$93.84 +1.49 (+1.61 %)
(As of 01/21/2019 01:20 AM ET)
Previous Close$93.84
Today's Range$90.00 - $95.55
52-Week Range$76.93 - $121.23
Volume61,852 shs
Average Volume68,210 shs
Market Capitalization$3.70 billion
P/E Ratio15.18
Dividend YieldN/A
Beta0.4
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Zrt.

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-4847-5700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$661.91 million
Cash Flow$6.7076 per share
Book Value$56.06 per share

Profitability

Net Income$211.15 million

Miscellaneous

Employees1,490
Market Cap$3.70 billion
OptionableOptionable

Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How often does Taro Pharmaceutical Industries pay dividends? What is the dividend yield for Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries announced a dividend on Monday, November 5th. Shareholders of record on Tuesday, December 11th will be paid a dividend of $12.81 per share on Friday, December 28th. The ex-dividend date of this dividend is Monday, December 10th. View Taro Pharmaceutical Industries' Dividend History.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced its quarterly earnings data on Monday, November, 5th. The company reported $1.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.96 by $0.36. The business had revenue of $158.97 million for the quarter, compared to the consensus estimate of $167.40 million. Taro Pharmaceutical Industries had a net margin of 36.33% and a return on equity of 11.99%. View Taro Pharmaceutical Industries' Earnings History.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Taro Pharmaceutical Industries.

What price target have analysts set for TARO?

1 brokerages have issued 12-month price objectives for Taro Pharmaceutical Industries' shares. Their predictions range from $115.00 to $115.00. On average, they anticipate Taro Pharmaceutical Industries' stock price to reach $115.00 in the next year. This suggests a possible upside of 22.5% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries.

What is the consensus analysts' recommendation for Taro Pharmaceutical Industries?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries.

What are Wall Street analysts saying about Taro Pharmaceutical Industries stock?

Here are some recent quotes from research analysts about Taro Pharmaceutical Industries stock:
  • 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We ascribe a price objective of $115 per share, based on a forward EPS multiple of 15.5x applied to our current fiscal 2019 EPS forecast of $7.40 per share." (12/10/2018)
  • 2. According to Zacks Investment Research, "Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals used in their production. Products are sold through wholesalers, generic drug distributors, drug store chains, mass merchandisers, HMOs, food stores, pharmacies and hospitals. " (10/11/2018)

Has Taro Pharmaceutical Industries been receiving favorable news coverage?

Headlines about TARO stock have trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Taro Pharmaceutical Industries earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.

Who are some of Taro Pharmaceutical Industries' key competitors?

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Uday V. Baldota, CEO & Director (Age 49)
  • Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 46)
  • Mr. Itamar Karsenti, VP & Head of Global Operations (Age 47)
  • Mr. Itzik Baruch, VP of Technical Services (Age 56)
  • Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 72)

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Hudson Capital Management LLC (0.03%).

Which institutional investors are buying Taro Pharmaceutical Industries stock?

TARO stock was purchased by a variety of institutional investors in the last quarter, including Hudson Capital Management LLC.

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $93.84.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $3.70 billion and generates $661.91 million in revenue each year. The company earns $211.15 million in net income (profit) each year or $6.18 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,490 workers across the globe.

What is Taro Pharmaceutical Industries' official website?

The official website for Taro Pharmaceutical Industries is http://www.taro.com.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKTOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]


MarketBeat Community Rating for Taro Pharmaceutical Industries (NYSE TARO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  381
MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TARO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TARO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel